Last updated on: 1/19/2009 | Author:

Don H. Catlin, MD Biography

Founder and CEO of Anti-Doping Research
Professor Emeritus of Molecular and Medical Pharmacology at the UCLA David Geffen School of Medicine
Con to the question "Should Performance-Enhancing Drugs Be Accepted in Sports?"

“If you try to get every last little cheater, you’re going to be pretty frustrated. There are always going to be ways to beat testing. But if you don’t test, sport is gone, it really is. Then you might say, well, OK, everybody is going to be on drugs, and they will all be equal again. But people will start getting really sick. All these things are toxic.”

“The Steroid Detective,” US News and World Report, Dec. 12, 2004

Involvement and Affiliations:
  • Chairman, Equine Drug Research Institute’s Scientific Advisory Committee, 2008-present
  • Professor Emeritus, Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, 2007-present
  • Founder and CEO, Anti-Doping Research, 2005-present
  • Member, International Olympic Committee Medical Commission, 1988-present
  • Member, World Anti-Doping Agency Health, Medical and Research Committee, 2006-2008
  • Director, UCLA Olympic Analytical Laboratory, 1982-2007
  • Professor, Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, 1972-2007
  • Recipient, Sportsman of the Year, Chicago Tribune, 2003
  • Founder, UCLA Olympic Analytical Laboratory, 1982
  • MD, University of Rochester, 1965
  • BA, Statistics and Psychology, Yale University, 1960
  • Oversaw the drug testing at the 2002 Winter Olympic Games in Salt Lake City, 1996 Summer Olympic Games in Atlanta (anabolic agents), 1994 Soccer World Cup, and 1984 Summer Olympic Games in Los Angeles
  • Involved in drug testing for the US Olympic Committee, National Collegiate Athletic Association (NCAA), Major League Baseball’s minor leagues, and the National Football League
  • Developed the testing methodology that differentiates natural from artificial testosterone, inaugurated the test for darbepoetin (a form of EPO), first reported the use of a designer steroid (norbolethone) in sport, and, in the investigation of Bay Area Laboratory Co-operative (BALCO), first identified THG (a designer steroid)